For patients with a new lymphoma diagnosis, the initial shock and anxiety are paramount. Clinicians should first focus on establishing a trusting relationship and providing emotional reassurance, deferring detailed treatment discussions until the patient is more settled.

Immediate therapy is not always required for mesothelioma. For older patients with incidentally discovered, asymptomatic, and slow-growing disease, active observation is a reasonable clinical strategy. This approach avoids treatment-related toxicity while keeping a close watch on disease progression.

While ctDNA testing offers powerful prognostic information, some patients decline it. The key reason is the anxiety associated with receiving a positive result after adjuvant therapy when there is no standard-of-care intervention for MRD positivity. For these patients, the psychological burden of knowing about likely recurrence without a clear action plan outweighs the benefit.

Experts predict that emerging cell-free DNA (ctDNA) tests for lymphoma will shift treatment from fixed durations to a response-adapted approach. Monitoring minimal residual disease via ctDNA will allow clinicians to tailor the length of therapy based on the quality of response.

When communicating with anxious, newly diagnosed patients, oncologists can point to the long-term survival 'tail' on modern immunotherapy trial curves. Simply stating, 'there is a chance that you will be alive and well,' provides crucial hope, reduces anxiety, and helps patients better engage with their treatment plan.

Despite new therapies for follicular lymphoma (FL), bendamustine-rituximab (BR) will likely remain the community standard due to its simplicity. This may create a growing gap in treatment approaches between academic centers using novel agents and community practices favoring the familiar BR regimen.

A powerful counseling technique for complex adjuvant therapy decisions is to ask patients: "If your cancer recurs, will you look back and regret the choice you're making today?" This forces patients to confront their own risk tolerance and helps them commit to a treatment path.

An expert oncologist intentionally does not discuss poor prognostic biomarkers like MYC amplification or p53 loss with patients. Since these factors cannot be targeted with current therapies, revealing them provides no clinical benefit and only causes patient distress.

While standard guidelines dictate treating only symptomatic CLL, some patients experience debilitating anxiety from 'watch and wait.' In rare cases, clinicians may initiate therapy primarily to improve quality of life by removing this significant psychological stress.